Acute Heart Failure (AHF)
Therapeutics Market Drivers
The global Acute
Heart Failure Therapeutics Market is expected to witness significant growth
due to approval of new drugs. For instance, in July 2015, Novartis received
U.S. Food and Drug Administration (FDA) approval for their Entresto(TM)
(sacubitril/valsartan) tablets on the treatment of heart failure with reduced
ejection fraction. Entresto is indicated to reduce the risk of cardiovascular
death and heart failure hospitalization.
Furthermore, robust pipeline of
drugs over the forecast period (2018-2026), is another factor driving growth of
acute heart failure therapeutics market. For instance, in March 2017, Cardioxyl
Pharmaceuticals’ CXL-1427: a novel nitroxyl (HNO) donor (prodrug), which now
operates under the Bristol-Myers Squibb Company (after Cardioxyl
Pharmaceuticals’ acquisition by Bristol-Myers Squibb in December 2015); is
present in Phase 2 clinical development phase. CXL-1427 is indicated to use as
an intravenous treatment for acute decompensated heart failure (ADHF).
Successful completion and further launch of Bristol-Myers Squibb’s innovative
drug in future, will help to boost the acute heart failure (AHF) therapeutics
market growth during the forecast period.
Various lifestyle factors are
responsible to increase risk heart attack and stroke, which includes smoking,
overweight, eating foods with high fat and cholesterol, and physical
inactivity. Furthermore, patients suffering with heart failure are at high risk
to one or more conditions such as coronary artery disease, myocardial
infraction, high blood pressure or hypertension, abnormal heart valves, dilated
cardiomyopathy, hypertrophic cardiomyopathy, severe lung disease, obesity, and
sleep apnea, among others. For instance, according to the World Health
Organization (WHO), October 2017 data findings, in 2016, over 1.9 billion
adults, were overweight, worldwide. Among which over 650 million were obese.
Moreover, according to the same source, raised BMI index, owing to overweight
and obesity are the major risk factors for cardiovascular disease, which was
the leading cause of death in 2012, worldwide.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1910
Acute heart failure (AHF) is a
progressive condition, in which, the heart muscle is unable to pump enough
blood through the heart to meet body’ optimal blood and oxygen level.
Congestive heart failure is type of heart failure which requires timely medical
attention. Moreover, distinguish between acute and chronic heart failure is
important from a clinical standpoint, on which further medication depends. For
this, N terminal proB-type natriuretic peptide levels are used for
distinguishing acute versus chronic left ventricular dysfunction. An elevated
levels of natriuretic peptide were present in patients with acute heart failure
compared to those with chronic heart failure patient.
Heart failure symptoms vary
widely from person to person, depending on types of heart failure patient. The
main symptoms of heart failure are caused due to fluid accumulation or
congestion and poor blood flow to the body. Symptoms caused by fluid
accumulation or congestion includes shortness of breath, weight gain, coughing,
swollen ankles, legs or abdomen, while dizziness, rapid heart rate, and fatigue
are symptoms associated with reduced blood flow to parts of the body.
Acute Heart Failure (AHF)
Therapeutics Market Restraints
Acute heart failure is a common
condition associated with considerable morbidity, mortality, and cost. However,
evidence-based data on treating heart failure in the acute setting are limited,
and current individual treatment options have variable efficacy. Furthermore,
healthcare team often need to customize patient care in acute heart failure
treatment. For instance, dyspnea is the most common symptom associated with AHF
patients. However, this symptom is non-specific as other medical conditions are
commonly associated with dyspnea, including pneumonia, exacerbations of chronic
obstructive pulmonary disease, pulmonary embolism, acute coronary syndrome, and
asthma. This is another factor negatively affecting growth of the acute heart
failure (AHF) therapeutics market.
Acute Heart Failure (AHF)
Therapeutics Market – Regional Analysis
Geographically, the market is
segmented into North America, Latin America, Europe, Middle East, Asia Pacific,
and Africa. North America is expected to hold dominant position in global acute
heart failure (AHF) therapeutics market, due to high prevalence of acute heart
failure cases, in this region. For instance, according to Centers for Disease
Control and Prevention (CDC), June 2016, around 5.7 million adults in the U.S.
suffered from heart failure, in 2016. Moreover, about half of the people who
develop heart failure die within 5 years of diagnosis.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/acute-heart-failure-ahf-therapeutics-market-1910
Furthermore, growing prevalence
of obesity have increased risk of developing acute heart failure (AHF).
According to CDC, May 2017 data findings, between 2013 and 2014, 37.9% of
adults aged 20 years and over were obese, in the U.S. Therefore, high
prevalence of risk factors and acute heart failure (AHF) cases in these region
are expected to drive growth of this market over the forecast period.
Asia Pacific acute heart failure
(AHF) therapeutics market is projected to witness significant growth, due to
increasing focus of healthcare organizations in creating awareness regarding
increasing risk factors of acute heart failure. For instance, in June 2016,
Fortis Hospital, India launched Fortis Heart Rhythm and Heart failure Centre in
Bangalore, to increase awareness among people regarding heart failure, stroke,
and various other cardiovascular disease.
Acute Heart Failure (AHF)
Therapeutics Market – Competitive Landscape
Some of the key players in this
market are Novartis AG, Cardiorentis AG, Bristol-Myers Squibb Company, Amgen
Inc., Bayer AG, Cytokinetics, Inc., Merck & Company, Inc., Ono
Pharmaceutical Co., Ltd., and Pfizer Inc., among others. Key players in the
marker are engaged in development of new drugs for acute heart failure (AHF).
These players are incorporating collaboration strategies to remain competitive
in the market.
For instance, in October 2015,
Cardiorentis AG announced plans to collaborate with Roche to establish
therapeutic efficacy and safety of Ularitide: Cardiorentis’ investigational
drug for acute heart failure (AHF). Under the terms of collaboration, Cardiorentis
will incorporate Roche's advanced in vitro diagnostic tests into its TRUE-AHF
Phase III study to characterize the pharmacological properties of Ularitide,
evaluate its benefit-risk profile, and the appropriate clinical application in
patients.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1910
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent Market
Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment